Skip to Content

Flunisolide nasal Pregnancy and Breastfeeding Warnings

Flunisolide nasal is also known as: Nasalide, Nasarel

Medically reviewed on Sep 7, 2018

Flunisolide nasal Pregnancy Warnings

Flunisolide has been assigned to pregnancy category C by the FDA. At high doses, flunisolide has been shown to be teratogenic in rabbits and rats. There are no controlled data in human pregnancy. Flunisolide is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

In a review of 229,101 deliveries to Michigan Medicaid patients, 141 first-trimester exposures to flunisolide and 322 exposures anytime during pregnancy were recorded. A total of 5 birth defects were reported with first-trimester exposures (5 expected). (written communication, Franz Rosa, MD, Food and Drug Administration, 1994) These data do not support an association with adverse fetal outcome.

See references

Flunisolide nasal Breastfeeding Warnings

There are no data on the excretion of flunisolide into human milk. Other glucocorticoids are excreted into human milk in low concentrations. The manufacturer recommends that caution be when administering flunisolide nasal to nursing women.

See references

References for pregnancy information

  1. "Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc, Palo Alto, CA.

References for breastfeeding information

  1. "Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc, Palo Alto, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.